A -- EVALUATION OF BIOLOGIC CORRELATES OR SURROGATE END POINTS IN THE TREATMENT OF KS

Notice Date

November 27, 2000

Contracting Office

National Cancer Institute, Research Contracts Branch, Office of the Chief, Executive Plaza South, MSC 7222, 6120 Executive Blvd., Room 608, Bethesda, MD 20892-7222

ZIP Code

20892-7222

Solicitation Number

AMC RFP #00-01

Response Due

January 16, 2001

Point of Contact

Brenda Hunter, 205/934-5165

E-Mail Address

Brenda Hunter, AMC Operations Center (hunter@cirrus.biosccc.uab.edu )

Description

The AIDS Associated Malignancies Clinical Trials Consortium (AMC) is soliciting specialized expertise to identify, develop and validate clinically practical tools for assessing the biological effects of targeted agents against KS, and to use these tools to explore correlations with therapeutic efficacy and other patient outcomes. Through responses to this RFP, the AMC hopes to incorporate, in an exploratory fashion, novel assays that may reflect the activity of an agent of interest on a specific biologic endpoint. If the results are found to be reproducible and to change consistently with therapy, such assays may be a useful way to screen novel agents in the future, and monitor patients in later phase trials. Interested parties can view the solicitation at the following URL: http://www.amc.uab.edu, under "Announcements" Please direct any questions to: Brenda Hunter, AMC Operations Center, University of Alabama at Birmingham, 2001 3rd Avenue South Room 1078 Birmingham, Alabama 35233, Phone: 205/934-5165, Fax: 205/975-7453 e-mail: hunter@cirrus.biosccc.uab.edu

Web Link

AIDS Malignancy Consortium (AMC) Home Page (http://www.amc.uab.edu)

Record

Loren Data Corp. 20001129/ASOL002.HTM (W-332 SN5074L7)